Isolation and Characterization of Human Umbilical Cord-derived Mesenchymal Stem Cells from Preterm and Term Infants
| Autor: | Jumpei Kuroda, Noriyuki Nishimura, Sota Iwatani, Khin Kyae Mon Thwin, Tsubasa Koda, Makiko Yoshida, Nanako Nino, Masahiro Nishiyama, Masami Mizobuchi, Hiroaki Nagase, Daisuke Kurokawa, Keiji Yamana, Kazumichi Fujioka, Kazumoto Iijima, Satoru Takafuji, Ichiro Morioka, Suguru Uemura |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
General Chemical Engineering Population Cell Separation Umbilical cord General Biochemistry Genetics and Molecular Biology Umbilical Cord Andrology Cell therapy 03 medical and health sciences 0302 clinical medicine Pregnancy Placenta medicine Adipocytes Humans CD90 030212 general & internal medicine education Cells Cultured Cell Proliferation Fetus education.field_of_study General Immunology and Microbiology business.industry General Neuroscience Mesenchymal stem cell Infant Newborn Cell Differentiation Mesenchymal Stem Cells 030104 developmental biology medicine.anatomical_structure Female Bone marrow business Infant Premature |
| Zdroj: | Journal of Visualized Experiments. |
| ISSN: | 1940-087X |
| DOI: | 10.3791/58806-v |
| Popis: | Mesenchymal stem cells (MSCs) have considerable therapeutic potential and attract increasing interest in the biomedical field. MSCs are originally isolated and characterized from bone marrow (BM), then acquired from tissues including adipose tissue, synovium, skin, dental pulp, and fetal appendages such as placenta, umbilical cord blood (UCB), and umbilical cord (UC). MSCs are a heterogeneous cell population with the capacity for (1) adherence to plastic in standard culture conditions, (2) surface marker expression of CD73+/CD90+/CD105+/CD45-/CD34-/CD14-/CD19-/HLA-DR- phenotypes, and (3) trilineage differentiation into adipocytes, osteocytes, and chondrocytes, as currently defined by the International Society for Cellular Therapy (ISCT). Although BM is the most widely used source of MSCs, the invasive nature of BM aspiration ethically limits its accessibility. Proliferation and differentiation capacity of MSCs obtained from BM generally decline with the age of the donor. In contrast, fetal MSCs obtained from UC have advantages such as vigorous proliferation and differentiation capacity. There is no ethical concern for UC sampling, as it is typically regarded as medical waste. Human UC starts to develop with continuing growth of the amniotic cavity at 4-8 weeks of gestation and keeps growing until reaching 50-60 cm in length, and it can be isolated during the whole newborn delivery period. To gain insight into the pathophysiology of intractable diseases, we have used UC-derived MSCs (UC-MSCs) from infants delivered at various gestational ages. In this protocol, we describe the isolation and characterization of UC-MSCs from fetuses/infants at 19-40 weeks of gestation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|